Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

95.35 +1.05 (+1.11%)
Streaming Delayed Price Updated: 10:52 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about S&P Biotech SPDR

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities
Via Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
Via Benzinga
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
Stryker, DaVita And These 2 ETFs: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named the  SPDR S&P Biotech ETF (NYSE: XBI), saying if you "want growth, 
Via Benzinga
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%. 
Via Talk Markets
2 ETFs That Can Set You Up for Life
Simplifying your investment strategy can help minimize your risk while still allowing you to earn some great returns. 
Via The Motley Fool
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength. 
Via Talk Markets
The Fed Should Stop Right Now
A pause to refresh or a mild pullback would be good for the stock market after running hot and heavy. On Wednesday, we saw weaker economic data in retail sales. Unlike previous soft data, the stock... 
Via Talk Markets
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing. 
Via Talk Markets
Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing”
Small-cap speculative biotech stocks regain interest with volatility. 
Via Talk Markets
3 Unstoppable ETFs to Stock Up On in 2023
These ETFs could be big winners in the new year. 
Via The Motley Fool
ETFs To Buy For 2023 After S&P 500's Worst Year Since 2008
The S&P 500 has dropped 19.4% in 2022. It marked the largest calendar-year decline since a 38% plunge in Lehman Bother’s crisis-laden 2008. Goldman Sachs, Bank of America and JPMorgan predict a U.S.... 
Via Talk Markets
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
5 Top Stocks for January
Now is the time to begin crafting your watch list for 2023. 
Via The Motley Fool
The Year In Review And Ahead
We‘ll continue witnessing cost-push inflation combined with tight labor market – and it would be crude oil‘s time again to gain in value from current levels. 
Via Talk Markets
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
Tuesday Talk: Where is Santa?
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found. 
Via Talk Markets
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning. 
Via Talk Markets
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead
Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets. 
Via Talk Markets
The 10 Most Shorted ETFs: Which Sectors Saw Short Interest Increase?
Investors often short stocks to hedge positions against long positions or as a way to bet against a particular company. Benzinga provides a look at the most shorted stocks here. 
Via Benzinga
My 3 Top Biotech Stock Picks for 2023
Biotech stocks are set to shine in 2023. 
Via The Motley Fool
Stocks Drop On November 17 As The Dollar Moves Higher
Stocks dropped as the dollar pushed higher ahead of options expiration. 
Via Talk Markets
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
Biotech stocks were hammered Wednesday, including several that had good news. 
Via Investor's Business Daily
2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter
These two healthcare stocks could deliver market-crushing gains by year's end. 
Via The Motley Fool
What To Watch In The S&P Biotech ETF After Johnson & Johnson's $16.6B Abiomed Deal
As the exodus out of mega-cap technology stocks continues, investors and money managers are looking for other sectors to rotate into. 
Via Benzinga
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS